dc.contributor.author | Saral, Aysegul | |
dc.contributor.author | Leonard, David A. | |
dc.contributor.author | Duzgun, Azer Ozad | |
dc.contributor.author | Cicek, Aysegul Copur | |
dc.contributor.author | June, Cynthia M. | |
dc.contributor.author | Sandalli, Cemal | |
dc.date.accessioned | 2021-11-09T19:41:48Z | |
dc.date.available | 2021-11-09T19:41:48Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 0021-8820 | |
dc.identifier.uri | https://doi.org/10.1038/ja.2016.48 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12440/3088 | |
dc.description.abstract | The class A p-lactamase GES-22 has been identified in Acinetobacter baumannii isolates in Turkey, and subsequently shown to differ from GES-11 by a single substitution (M169L). Because M169 is part of the omega loop, a structure that is known to have major effects on substrate selectivity in class A beta-lactamases, we expressed, purified and kinetically characterized this novel variant. Our results show that compared with GES-11(6xHis), GES-22(6xHis) displays more efficient hydrolysis of penicillins, and aztreonam, but a loss of efficiency against ceftazidime. In addition, the M169L substitution confers on GES-22 more efficient hydrolysis of the mechanistic inhibitors clavulanic acid and sulbactam. These effects are highly similar to other mutations at the homologous position in other class A beta-lactamases, suggesting that this methionine has a key structural role in aligning active site residues and in substrate selectivity across the class. | en_US |
dc.description.sponsorship | Recep Tayyip Erdogan UniversityRecep Tayyip Erdogan University [BAP-2013.102.03.12]; Scientific and Technical Research Council of TurkeyTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [TUBITAK-113Z054]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R15AI082416]; Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [2214-A]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R15AI082416] Funding Source: NIH RePORTER | en_US |
dc.description.sponsorship | This study was supported by grants from Recep Tayyip Erdogan University (BAP-2013.102.03.12), The Scientific and Technical Research Council of Turkey (TUBITAK-113Z054), National Institutes of Health grant 1R15AI082416 (D.A.L.) and a scholarship to A.S. from Scientific and Technological Research Council of Turkey (TUBITAK) (2214-A). | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Japan Antibiotics Research Assoc | en_US |
dc.relation.ispartof | Journal of Antibiotics | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Extended-Spectrum Cephalosporins | en_US |
dc.subject | Class D Carbapenemases | en_US |
dc.subject | Acinetobacter-Baumannii | en_US |
dc.subject | Pseudomonas-Aeruginosa | en_US |
dc.subject | Structural Basis | en_US |
dc.subject | Ceftazidime | en_US |
dc.subject | Resistance | en_US |
dc.subject | Enterobacteriaceae | en_US |
dc.subject | Inhibition | en_US |
dc.subject | Aztreonam | en_US |
dc.title | Kinetic characterization of GES-22 beta-lactamase harboring the M169L clinical mutation | en_US |
dc.type | article | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.description.wospublicationid | WOS:000390615900003 | en_US |
dc.description.scopuspublicationid | 2-s2.0-85006765791 | en_US |
dc.department | Gümüşhane Üniversitesi | en_US |
dc.authorid | DUZGUN, AZER OZAD / 0000-0002-6301-611X | |
dc.authorid | DUZGUN, AZER OZAD / 0000-0002-6301-611X | |
dc.authorid | SANDALLI, Cemal / 0000-0002-1298-3687 | |
dc.authorid | SARAL SARIYER, AYSEGUL / 0000-0002-7757-6812 | |
dc.identifier.volume | 69 | en_US |
dc.identifier.issue | 12 | en_US |
dc.identifier.startpage | 858 | en_US |
dc.identifier.doi | 10.1038/ja.2016.48 | |
dc.identifier.endpage | 862 | en_US |
dc.authorwosid | Cicek, Aysegul / AAM-6146-2021 | |
dc.authorwosid | DUZGUN, AZER OZAD / ABB-4068-2020 | |
dc.authorwosid | DUZGUN, AZER OZAD / A-1612-2018 | |
dc.authorscopusid | 55840169200 | |
dc.authorscopusid | 7201953952 | |
dc.authorscopusid | 55840997800 | |
dc.authorscopusid | 13105327500 | |
dc.authorscopusid | 40261684300 | |
dc.authorscopusid | 23989741700 | |
dc.description.pubmedpublicationid | PubMed: 27168312 | en_US |